Last $5.51 USD
Change Today +0.14 / 2.61%
Volume 374.9K
PACB On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 4:00 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

pacific biosciences of calif (PACB) Key Developments

Pacific Biosciences of California, Inc. expected to report Q2 2014 results on July 23, 2014. This event was calculated by Capital IQ (Created on July 5, 2014).

Pacific Biosciences of California, Inc. expected to report Q2 2014 results on July 23, 2014. This event was calculated by Capital IQ (Created on July 5, 2014).

Pacific Biosciences and GenDx Initiate Co-Marketing Activities for Full-Length HLA Gene Sequencing Products

Pacific Biosciences of California, Inc., and GenDx announced a co-marketing agreement to offer products for full-length HLA gene sequencing. The Human Leukocyte Antigen (HLA) system consists of a large family of highly variable genes and allelic variants that forms the basis of the human immune system. High-resolution HLA typing and sequencing of the complete gene enables determination of even the smallest variations between HLA alleles. HLA allele-specific genotyping is critical for autoimmune disease-association studies, drug hypersensitivity research and other applications. Thus, there has been an ever growing interest in characterizing the HLA genes in their entirety. GenDx, which currently offers reagents for the amplification of full-length, Class I HLA genes, will offer a version of its NGSgo(R) reagent line with barcoded primers developed with Pacific Biosciences for sequencing on the PacBio RS II DNA sequencing system. Using the GenDx NGSengine(R) software package to analyze data from the PacBio system provides customers with a highly accurate, allele-level HLA typing solution. This new reagent kit will allow the pooling of full-length, Class I HLA genes from multiple samples into a single sequencing run.

Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Year 2014

Pacific Biosciences of California, Inc. announced that it will be providing an update to 2014 financial forecast. Starting with revenue, the company is increasing revenue growth forecast for the year, from 55% previously to approximately 70%, which translates a total annual revenue estimate of between $47 million and $48 million for 2014.

Pacific Biosciences of California, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2014

Pacific Biosciences of California, Inc. announced unaudited consolidated financial results for the first quarter ended March 31, 2014. For the quarter, revenue for totaled $11.6 million, compared to $5.6 million for the first quarter of 2013. First quarter 2014 revenue reflects the installation of nine PacBio(R) RS II systems, compared to three PacBio(R) RS systems during the first quarter of 2013. Total revenue for the first quarter of 2014 also included $1.7 million of revenue recognized pursuant to a development agreement the company entered into with Roche Diagnostics during September 2013. The net loss for the first quarter of 2014 was $18.9 million or $0.28 per basic and diluted share compared to $21.1 million or $0.37 per basic and diluted share for the first quarter of 2013. Operating loss was $18.245 million compared to $20.607 million reported a year ago.

HistoGenetics Selects Pacific Biosciences of California, Inc. DNA Sequencing Platform to Enhance Human Leukocyte Antigen Typing

Pacific Biosciences of California, Inc. announced that HistoGenetics has selected the PacBio DNA Sequencing platform for its unique ability to sequence full-length HLA genes and to provide fully phased HLA alleles. HistoGenetics has purchased two PacBio RS II DNA Sequencing systems, which will be used for HLA typing and will be evaluated as potential replacements for Sanger sequencing. Comprehensive characterization of an individual's HLA type is important for research in tissue transplantation matching, autoimmune disease-association studies, drug hypersensitivity research, and other applications. The HLA genes are highly polymorphic, containing thousands of alleles that code for proteins that are important for recognizing foreign antigens. Accurate phasing of HLA polymorphisms using Sanger and short-read sequencing technologies has previously required confirmation, incurring additional expense. These methods also suffer from ambiguous calls when imputation data is required. The long read lengths (tens of thousands of bases) provided by PacBio sequencing are ideally suited for accurate allele-level genotyping since unambiguous allele phasing is critical for high-resolution allele assignment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PACB:US $5.51 USD +0.14

PACB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $8.56 USD +0.14
Fluidigm Corp $28.96 USD +1.40
IntelliCell BioSciences Inc $0.0015 USD 0.00
Luminex Corp $17.72 USD +0.29
Sequenom Inc $3.71 USD -0.03
View Industry Companies
 

Industry Analysis

PACB

Industry Average

Valuation PACB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.6x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIFIC BIOSCIENCES OF CALIF, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.